Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy

Immune checkpoint blockade therapies, especially those targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have achieved impressive clinical responses in multiple types of cancers. To optimize the therapeutic effect of the checkpoint antibodies, many strategies including target...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Liyan, Miao, Qianwei, Meng, Fanqiang, Li, Baoqi, Xue, Tianyuan, Fang, Tianliang, Zhang, Zhirang, Zhang, Jinxie, Ye, Xinyu, Kang, Yang, Zhang, Xingding, Chen, Qian, Liang, Xin, Chen, Hongbo, Zhang, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058713/
https://www.ncbi.nlm.nih.gov/pubmed/33897897
http://dx.doi.org/10.7150/thno.48868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058713/
https://www.ncbi.nlm.nih.gov/pubmed/33897897
http://dx.doi.org/10.7150/thno.48868

Ejemplares similares